Download PDF
Clin Colon Rectal Surg 2018; 31(05): 301-308
DOI: 10.1055/s-0038-1642054
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Small Bowel and Colorectal Carcinoids

Raphael M. Byrne
1   Division of General and Gastrointestinal Surgery, Department of Surgery, Oregon Health & Science University, Portland, Oregon
,
Rodney F. Pommier
2   Division of Surgical Oncology, Department of Surgery, Oregon Health & Science University, Portland, Oregon
› Author Affiliations
Further Information

Publication History

Publication Date:
04 September 2018 (online)

    Permissions and Reprints

Abstract

Neuroendocrine tumors, or carcinoid tumors, of both the midgut and hindgut are quite rare, but their incidence is increasing. Surgery is the treatment of choice in patients who can tolerate an operation and have operable disease. Options for the treatment of metastatic disease include cytoreductive surgery, somatostatin analogues, interferon α, local liver therapies (hepatic arterial embolization, ablation), chemotherapy, Peptide-Receptor Radionucleotide Radiotherapy, angiogenesis inhibitors, and mammalian target of rapamycin inhibitors.

Keywords

neuroendocrine tumors - carcinoid tumors - jejunoileal NET - appendiceal NET - colorectal NET
 

  • References

  • 1 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97 (04) 934-959
    CrossrefPubMedGoogle Scholar
  • 2 Yao JC, Hassan M, Phan A. , et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
    CrossrefPubMedGoogle Scholar
  • 3 Cross AJ, Leitzmann MF, Subar AF, Thompson FE, Hollenbeck AR, Schatzkin A. A prospective study of meat and fat intake in relation to small intestinal cancer. Cancer Res 2008; 68 (22) 9274-9279
    CrossrefPubMedGoogle Scholar
  • 4 Schatzkin A, Park Y, Leitzmann MF, Hollenbeck AR, Cross AJ. Prospective study of dietary fiber, whole grain foods, and small intestinal cancer. Gastroenterology 2008; 135 (04) 1163-1167
    CrossrefPubMedGoogle Scholar
  • 5 Avenel P, McKendrick A, Silapaswan S. , et al. Gastrointestinal carcinoids: an increasing incidence of rectal distribution. Am Surg 2010; 76 (07) 759-763
    PubMedGoogle Scholar
  • 6 Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17 (04) 909-918
    CrossrefPubMedGoogle Scholar
  • 7 Jetmore AB, Ray JE, Gathright Jr JB, McMullen KM, Hicks TC, Timmcke AE. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992; 35 (08) 717-725
    CrossrefPubMedGoogle Scholar
  • 8 Garcia-Carbonero R, Capdevila J, Crespo-Herrero G. , et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21 (09) 1794-1803
    CrossrefPubMedGoogle Scholar
  • 9 Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R. ; representatives of 21 German NET Centers. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 2009; 90 (04) 349-363
    CrossrefPubMedGoogle Scholar
  • 10 Ito T, Sasano H, Tanaka M. , et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010; 45 (02) 234-243
    CrossrefPubMedGoogle Scholar
  • 11 Toth-Fejel S, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg 2004; 187 (05) 575-579
    CrossrefPubMedGoogle Scholar
  • 12 Graff-Baker AN, Sauer DA, Pommier SJ, Pommier RF. Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients. Surgery 2014; 156 (06) 1369-1376 , discussion 1376–1377
    CrossrefPubMedGoogle Scholar
  • 13 Pape UF, Perren A, Niederle B. , et al; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95 (02) 135-156
    CrossrefPubMedGoogle Scholar
  • 14 Anthony LB, Strosberg JR, Klimstra DS. , et al; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas 2010; 39 (06) 767-774
    CrossrefPubMedGoogle Scholar
  • 15 Caplin M, Sundin A, Nillson O. , et al; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012; 95 (02) 88-97
    CrossrefPubMedGoogle Scholar
  • 16 Shields CJ, Tiret E, Winter DC. ; International Rectal Carcinoid Study Group. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg 2010; 252 (05) 750-755
    CrossrefPubMedGoogle Scholar
  • 17 Gleeson FC, Levy MJ, Dozois EJ, Larson DW, Wong Kee Song LM, Boardman LA. Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes. Gastrointest Endosc 2014; 80 (01) 144-151
    CrossrefPubMedGoogle Scholar
  • 18 Boudreaux JP, Klimstra DS, Hassan MM. , et al; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010; 39 (06) 753-766
    CrossrefPubMedGoogle Scholar
  • 19 Woltering E, Bergsland EK, Beyer DT. , et al. Neuroendocrine Tumors of the Jejunum and Ileum. AJCC Cancer Staging Manual, 8th ed. Chicago: Springer; 2017: 375
    Google Scholar
  • 20 Woltering E, Bergsland EK, Beyer DT. , et al. Neuroendocrine Tumors of the Appendix. AJCC Cancer Staging Manual, 8th ed. Chicago: Springer; 2017: 389
    Google Scholar
  • 21 Shi CWE, Woltering E, Beyer DT. , et al. Neuroendocrine Tumors of the Colon and Rectum. AJCC Cancer Staging Manual, 8th ed. Chicago: Springer; 2017: 395
    Google Scholar
  • 22 Mani S, Modlin IM, Ballantyne G, Ahlman H, West B. Carcinoids of the rectum. J Am Coll Surg 1994; 179 (02) 231-248
    PubMedGoogle Scholar
  • 23 Naunheim KS, Zeitels J, Kaplan EL. , et al. Rectal carcinoid tumors--treatment and prognosis. Surgery 1983; 94 (04) 670-676
    PubMedGoogle Scholar
  • 24 Fahy BN, Tang LH, Klimstra D. , et al. Carcinoid of the rectum risk stratification (CaRRS): a strategy for preoperative outcome assessment. Ann Surg Oncol 2007; 14 (02) 396-404
    CrossrefPubMedGoogle Scholar
  • 25 Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 1999; 85 (07) 1470-1483
    CrossrefPubMedGoogle Scholar
  • 26 Tormey WP, FitzGerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J 1995; 71 (839) 542-545
    CrossrefPubMedGoogle Scholar
  • 27 Kobayashi K, Katsumata T, Yoshizawa S. , et al. Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. Dis Colon Rectum 2005; 48 (02) 285-291
    CrossrefPubMedGoogle Scholar
  • 28 Ahmed A, Turner G, King B. , et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009; 16 (03) 885-894
    CrossrefPubMedGoogle Scholar
  • 29 Norlén O, Stålberg P, Öberg K. , et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 2012; 36 (06) 1419-1431
    CrossrefPubMedGoogle Scholar
  • 30 Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery 2016; 159 (01) 358-365
    CrossrefPubMedGoogle Scholar
  • 31 Kinney MA, Warner ME, Nagorney DM. , et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 2001; 87 (03) 447-452
    CrossrefPubMedGoogle Scholar
  • 32 Massimino K, Harrskog O, Pommier S, Pommier R. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol 2013; 107 (08) 842-846
    CrossrefPubMedGoogle Scholar
  • 33 Rinke A, Müller HH, Schade-Brittinger C. , et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27 (28) 4656-4663
    CrossrefPubMedGoogle Scholar
  • 34 Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371 (16) 1556-1557
    PubMedGoogle Scholar
  • 35 Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 2002; 65 (04) 200-206
    CrossrefPubMedGoogle Scholar
  • 36 Höpfner M, Schuppan D, Scherübl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. World J Gastroenterol 2008; 14 (16) 2461-2473
    CrossrefPubMedGoogle Scholar
  • 37 Yao JC, Fazio N, Singh S. , et al; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387 (10022): 968-977
    CrossrefPubMedGoogle Scholar
  • 38 Strosberg J, El-Haddad G, Wolin E. , et al; NETTER-1 Trial Investigators. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedGoogle Scholar